Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

William Fantegrossi to Mice

This is a "connection" page, showing publications William Fantegrossi has written about Mice.

 
Connection Strength
  
 
 
2.116
  
  1. Shaw HE, Patel DR, Gannon BM, Fitzgerald LR, Carbonaro TM, Johnson CR, Fantegrossi WE. Phencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents. J Pharmacol Exp Ther. 2024 Jun 21; 390(1):14-28.
    View in: PubMed
    Score: 0.115
  2. Fitzgerald LR, Gannon BM, Walther D, Landavazo A, Hiranita T, Blough BE, Baumann MH, Fantegrossi WE. Structure-activity relationships for locomotor stimulant effects and monoamine transporter interactions of substituted amphetamines and cathinones. Neuropharmacology. 2024 Mar 01; 245:109827.
    View in: PubMed
    Score: 0.111
  3. Gannon BM, Fitzgerald LR, Godwin CO, Hughes-Meredith HD, Rice KC, Fantegrossi WE. Effects of ambient temperature on locomotor activity and place conditioning elicited by abused psychostimulants in mice: Role of 3,4-methylenedioxy moiety. Drug Alcohol Depend. 2023 09 01; 250:110917.
    View in: PubMed
    Score: 0.108
  4. Wilson CD, Zheng F, Fantegrossi WE. Convulsant doses of abused synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA and JWH-018 do not elicit electroencephalographic (EEG) seizures in male mice. Psychopharmacology (Berl). 2022 Oct; 239(10):3237-3248.
    View in: PubMed
    Score: 0.101
  5. Wilson CD, Hiranita T, Fantegrossi WE. Cannabimimetic effects of abused indazole-carboxamide synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA and 5F-ADB-PINACA in mice: Tolerance, dependence and withdrawal. Drug Alcohol Depend. 2022 07 01; 236:109468.
    View in: PubMed
    Score: 0.099
  6. Russell LN, Hyatt WS, Gannon BM, Simecka CM, Randolph MM, Fantegrossi WE. Effects of Laboratory Housing Conditions on Core Temperature and Locomotor Activity in Mice. J Am Assoc Lab Anim Sci. 2021 05 01; 60(3):272-280.
    View in: PubMed
    Score: 0.092
  7. Berquist MD, Leth-Petersen S, Kristensen JL, Fantegrossi WE. Locomotor effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in mice: psychostimulant effects, stereotypy, and sensitization. Psychopharmacology (Berl). 2020 Feb; 237(2):431-442.
    View in: PubMed
    Score: 0.083
  8. Ford BM, Cabanlong CV, Tai S, Franks LN, Penthala NR, Crooks PA, Prather PL, Fantegrossi WE. Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with ?9-Tetrahydrocannabinol and JWH-018. J Pharmacol Exp Ther. 2019 05; 369(2):259-269.
    View in: PubMed
    Score: 0.079
  9. Wilson CD, Tai S, Ewing L, Crane J, Lockhart T, Fujiwara R, Radominska-Pandya A, Fantegrossi WE. Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice. J Pharmacol Exp Ther. 2019 02; 368(2):146-156.
    View in: PubMed
    Score: 0.078
  10. Tai S, Vasiljevik T, Sherwood AM, Eddington S, Wilson CD, Prisinzano TE, Fantegrossi WE. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice. Drug Alcohol Depend. 2018 11 01; 192:285-293.
    View in: PubMed
    Score: 0.077
  11. Gannon BM, Williamson A, Rice KC, Fantegrossi WE. Role of monoaminergic systems and ambient temperature in bath salts constituent 3,4-methylenedioxypyrovalerone (MDPV)-elicited hyperthermia and locomotor stimulation in mice. Neuropharmacology. 2018 05 15; 134(Pt A):13-21.
    View in: PubMed
    Score: 0.072
  12. Berquist MD, Hyatt WS, Bauer-Erickson J, Gannon BM, Norwood AP, Fantegrossi WE. Phencyclidine-like in?vivo effects of methoxetamine in mice and rats. Neuropharmacology. 2018 05 15; 134(Pt A):158-166.
    View in: PubMed
    Score: 0.071
  13. Gannon BM, Russell LN, Modi MS, Rice KC, Fantegrossi WE. Effects of orally self-administered bath salt constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice. Drug Alcohol Depend. 2017 10 01; 179:408-415.
    View in: PubMed
    Score: 0.071
  14. Gannon BM, Williamson A, Suzuki M, Rice KC, Fantegrossi WE. Stereoselective Effects of Abused "Bath Salt" Constituent 3,4-Methylenedioxypyrovalerone in Mice: Drug Discrimination, Locomotor Activity, and Thermoregulation. J Pharmacol Exp Ther. 2016 Mar; 356(3):615-23.
    View in: PubMed
    Score: 0.064
  15. Smith DA, Bailey JM, Williams D, Fantegrossi WE. Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice. J Pharmacol Exp Ther. 2014 Dec; 351(3):485-91.
    View in: PubMed
    Score: 0.058
  16. Fantegrossi WE, Gray BW, Bailey JM, Smith DA, Hansen M, Kristensen JL. Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT2A receptors, in mice. Psychopharmacology (Berl). 2015 Mar; 232(6):1039-47.
    View in: PubMed
    Score: 0.058
  17. Hyatt WS, Fantegrossi WE. ?9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/'Spice' constituent JWH-018 in mice. Behav Pharmacol. 2014 Jun; 25(3):253-7.
    View in: PubMed
    Score: 0.057
  18. Brents LK, Zimmerman SM, Saffell AR, Prather PL, Fantegrossi WE. Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy. J Pharmacol Exp Ther. 2013 Sep; 346(3):350-61.
    View in: PubMed
    Score: 0.054
  19. Fantegrossi WE, Xiao WR, Zimmerman SM. Novel technology for modulating locomotor activity as an operant response in the mouse: implications for neuroscience studies involving "exercise" in rodents. J Neurosci Methods. 2013 Jan 30; 212(2):338-43.
    View in: PubMed
    Score: 0.051
  20. Fantegrossi WE, Gannon BM, Zimmerman SM, Rice KC. In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology. 2013 Mar; 38(4):563-73.
    View in: PubMed
    Score: 0.051
  21. Murnane KS, Perrine SA, Finton BJ, Galloway MP, Howell LL, Fantegrossi WE. Effects of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: correlations between behavior and neurochemistry. Psychopharmacology (Berl). 2012 Apr; 220(3):495-508.
    View in: PubMed
    Score: 0.048
  22. Fantegrossi WE, Simoneau J, Cohen MS, Zimmerman SM, Henson CM, Rice KC, Woods JH. Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice. J Pharmacol Exp Ther. 2010 Dec; 335(3):728-34.
    View in: PubMed
    Score: 0.044
  23. Goeders JE, Murnane KS, Banks ML, Fantegrossi WE. Escalation of food-maintained responding and sensitivity to the locomotor stimulant effects of cocaine in mice. Pharmacol Biochem Behav. 2009 Jul; 93(1):67-74.
    View in: PubMed
    Score: 0.040
  24. Fantegrossi WE, Murai N, Math?na BO, Pizarro N, de la Torre R. Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations. J Pharmacol Exp Ther. 2009 Jun; 329(3):1006-15.
    View in: PubMed
    Score: 0.040
  25. Fantegrossi WE, Ciullo JR, Wakabayashi KT, De La Garza R, Traynor JR, Woods JH. A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience. 2008 Jan 24; 151(2):533-43.
    View in: PubMed
    Score: 0.036
  26. Fantegrossi WE, Reissig CJ, Katz EB, Yarosh HL, Rice KC, Winter JC. Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents. Pharmacol Biochem Behav. 2008 Jan; 88(3):358-65.
    View in: PubMed
    Score: 0.036
  27. Fantegrossi WE, Kugle KM, Valdes LJ, Koreeda M, Woods JH. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav Pharmacol. 2005 Dec; 16(8):627-33.
    View in: PubMed
    Score: 0.032
  28. Fantegrossi WE, Harrington AW, Eckler JR, Arshad S, Rabin RA, Winter JC, Coop A, Rice KC, Woods JH. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology (Berl). 2005 Sep; 181(3):496-503.
    View in: PubMed
    Score: 0.031
  29. Fantegrossi WE, Kiessel CL, De la Garza R, Woods JH. Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology (Berl). 2005 Sep; 181(3):529-36.
    View in: PubMed
    Score: 0.031
  30. Fantegrossi WE, Kiessel CL, Leach PT, Van Martin C, Karabenick RL, Chen X, Ohizumi Y, Ullrich T, Rice KC, Woods JH. Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology (Berl). 2004 May; 173(3-4):270-7.
    View in: PubMed
    Score: 0.028
  31. Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ullrich T, Rice KC, Woods JH. Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl). 2003 Mar; 166(3):202-11.
    View in: PubMed
    Score: 0.026
  32. Cabanlong CV, Russell LN, Fantegrossi WE, Prather PL. Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors. Toxicol Sci. 2022 04 26; 187(1):175-185.
    View in: PubMed
    Score: 0.025
  33. Pinson A, Yarbrough AL, Bush JM, Cabanlong CV, Shoeib A, Jackson BK, Fukuda S, Gogoi J, Fantegrossi WE, McCain K, Prather PL, Fujiwara R, Radominska-Pandya A. Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity. Pharmacol Biochem Behav. 2020 08; 195:172949.
    View in: PubMed
    Score: 0.022
  34. Hay CE, Ewing LE, Hambuchen MD, Zintner SM, Small JC, Bolden CT, Fantegrossi WE, Margaritis P, Owens SM, Peterson EC. The Development and Characterization of an scFv-Fc Fusion-Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse. J Pharmacol Exp Ther. 2020 07; 374(1):16-23.
    View in: PubMed
    Score: 0.021
  35. Ford BM, Franks LN, Tai S, Fantegrossi WE, Stahl EL, Berquist MD, Cabanlong CV, Wilson CD, Penthala NR, Crooks PA, Prather PL. Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development. Pharmacol Res. 2017 Nov; 125(Pt B):161-177.
    View in: PubMed
    Score: 0.018
  36. Farrell MS, McCorvy JD, Huang XP, Urban DJ, White KL, Giguere PM, Doak AK, Bernstein AI, Stout KA, Park SM, Rodriguiz RM, Gray BW, Hyatt WS, Norwood AP, Webster KA, Gannon BM, Miller GW, Porter JH, Shoichet BK, Fantegrossi WE, Wetsel WC, Roth BL. In Vitro and In Vivo Characterization of the Alkaloid Nuciferine. PLoS One. 2016; 11(3):e0150602.
    View in: PubMed
    Score: 0.016
  37. Vasiljevik T, Franks LN, Ford BM, Douglas JT, Prather PL, Fantegrossi WE, Prisinzano TE. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse. J Med Chem. 2013 Jun 13; 56(11):4537-50.
    View in: PubMed
    Score: 0.013
  38. Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies. Neuropharmacology. 2012 Oct; 63(5):905-15.
    View in: PubMed
    Score: 0.013
  39. Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol. 2012 Apr 01; 83(7):952-61.
    View in: PubMed
    Score: 0.012
  40. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One. 2011; 6(7):e21917.
    View in: PubMed
    Score: 0.012
  41. Matsumoto RR, Li SM, Katz JL, Fantegrossi WE, Coop A. Effects of the selective sigma receptor ligand, 1-(2-phenethyl)piperidine oxalate (AC927), on the behavioral and toxic effects of cocaine. Drug Alcohol Depend. 2011 Oct 01; 118(1):40-7.
    View in: PubMed
    Score: 0.011
  42. Legendre O, Pecic S, Chaudhary S, Zimmerman SM, Fantegrossi WE, Harding WW. Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15; 20(2):628-31.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.